Halberd Corporation and GTX Corp (OTCMKTS:HALB) are coming together to work on several neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, PTSD/CTE (Chronic Traumatic Encephalopathy)/ Traumatic Brain Injury), among others.
Seniors, active duty and veteran soldiers, participants in contact sports and millions of people in general, are susceptible to these diseases, but there is finally some promising news. Both companies plan to combine their technology and expertise in the field to develop superior diagnostics/treatments for these diseases and afflictions.
Halberd’s Vita-Shield-MaxTM Immune Support nutraceutical, which boosts natural immunity defenses, will be up for sale by GTX, and can be accessed on GTX’s ecommerce website. It can be purchased via Halberd’s website, www.vitashieldmax.com as well as Amazon.
GTX Corp CEO, Patrick Bertagna, says that a majority of their client base suffers from Alzheimer’s, dementia, autism and traumatic brain injury, and the company works with the military too, so they are thrilled to collaborate with Halberd on this project to further assist in developing and testing unique treatments and solutions for neurodegenerative diseases. William A. Hartman, Chairman, President and CEO of Halberd Corporation, emphasizes that this agreement is an excellent way to utilize GTX’s existing telemetry/ telecommunications systems and combine it with their revolutionary medical treatment technology being developed in conjunction with their university research partners.
Market Reaction:
On Tuesday, HALB stock remain unchanged at $0.0270 with more than 2.22 million shares, compared to its average volume of 11.56 million shares. The stock has moved within a range of $0.0257 – 0.0283 after opening the trade at $0.0270.
